mAbxience |

Bio 2021


Meet us at BIO, to be held 14-17 June. 2021.

Spanish group Insud Pharma signs agreement with AstraZeneca to manufacture COVID-19 vaccine candidate


The plant in Spain’s Castilla-La Mancha region will undertake vial filling and packaging for AZD1222 The company also provides drug substance manufacturing for AZD1222 through their site in Argentina Insud Pharma is at the forefront of Spanish companies in investment in R&D The Spanish pharmaceutical group Insud Pharma will provide vial filling and packaging of […]

CPhI Worldwide 2021


Meet us at CPHI, to be held 9-11 November in Milan, Italy. 2021.

mAbxience enters into an agreement with AstraZeneca to produce Covid-19 vaccine


mAbxience, the biotec company of the Spanish Insud Pharma group, is deeply proud to announce that has entered into an agreement with AstraZeneca to produce a Covid-19 vaccine in Latin America. Our recently inaugurated plant in Garín (Argentina) will produce the active ingredient, which will subsequently be sent to Mexico to complete the production and […]

Insud Pharma secures “Excellent” rating in the Profarma programme


The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained the “EXCELLENT” rating in the Profarma Plan 2019, in recognition of their industrial activity and their commitment to development and innovation. After four consecutive years of obtaining the “Very Good” rating, this plan, an initiative of the Ministry of Industry, […]

Making available free paediatric medicine can accelerate elimination of congenital Chagas disease


The donation of an essential antiparasitic medicine can potentially accelerate the elimination of Chagas disease infection in children. A pediatric presentation of benznidazole with accurate dosage and will soon be made available freely to address a long-standing gap in the treatment of congenital infections of Chagas disease. The donation, by the Mundo Sano Foundation1 and […]